Sun Pharma Wins Favorable Lipitor Antitrust Ruling In US Appeal

The U.S. Third Circuit affirmed summary judgment entirely in favour of Sun Pharmaceutical and subsidiaries in antitrust litigation concerning the 2008 generic Lipitor settlement with Pfizer, and upheld denial of class certification. The decision substantially closes the matter, subject to any further remedies available to plaintiffs.